Stavros S Niarchos

Seno Medical Inks Exclusive Agreement with Genetik, Inc. as Distributor for Imagio® Breast Imaging System in Southeast Asia

Retrieved on: 
Friday, January 13, 2023

San Antonio, TX, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Seno Medical has entered into an exclusive distributor agreement with Genetik, Inc., to market, sell and service the company’s groundbreaking Imagio® Opto-Acoustic/Ultrasound (OA/US) Breast Imaging System.

Key Points: 
  • San Antonio, TX, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Seno Medical has entered into an exclusive distributor agreement with Genetik, Inc., to market, sell and service the company’s groundbreaking Imagio® Opto-Acoustic/Ultrasound (OA/US) Breast Imaging System.
  • This distributor agreement – a first for Seno – will enable Genetik to regionally distribute the Imagio® System in Singapore, where the distributor is headquartered.
  • Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

Retrospective Study of Seno Medical’s Imagio® Breast Imaging System Published in American Journal of Roentgenology Shows System May Help Reduce Biopsies of Benign Breast Masses Compared to Ultrasound Alone

Retrieved on: 
Thursday, January 5, 2023

The study, Optoacoustic Imaging with Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study , shows that optoacoustic imaging with decision support may help reduce biopsies of benign breast masses compared with grayscale ultrasound interpretation alone, while maintaining 98 percent sensitivity for cancer.

Key Points: 
  • The study, Optoacoustic Imaging with Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study , shows that optoacoustic imaging with decision support may help reduce biopsies of benign breast masses compared with grayscale ultrasound interpretation alone, while maintaining 98 percent sensitivity for cancer.
  • The reader study included 480 patients with 480 breast masses that had been classified by conventional grayscale ultrasound.
  • Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography.

Seno Medical Launches its Scans Across America Mobile Bus Tour for Hands-on Demonstrations Throughout the USA of the Imagio® Breast Imaging System

Retrieved on: 
Tuesday, August 9, 2022

Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.

Key Points: 
  • Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.
  • Senos OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • The Imagio OA/US Road Show - Scans Across America tour will feature continued stops across the country throughout 2022.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

Edison Awards Program Honors Seno Medical’s Imagio® Breast Imaging System With a “Best of the Best” GOLD Award

Retrieved on: 
Monday, April 25, 2022

San Antonio, TX, April 25, 2022 (GLOBE NEWSWIRE) -- Seno Medicals ImagioBreast Imaging System has been selected by the Edison Awards program as a GOLD award winner in the Science & Medical category.

Key Points: 
  • San Antonio, TX, April 25, 2022 (GLOBE NEWSWIRE) -- Seno Medicals ImagioBreast Imaging System has been selected by the Edison Awards program as a GOLD award winner in the Science & Medical category.
  • Being recognized with an Edison Award is one of the highest accolades a company can receive in the name of innovation and business success.
  • The Edison Awards honor excellence in new product and service development, marketing, human-centered design, and innovation.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Seno Medical’s Imagio® Breast Imaging System Selected As GOLD Winner in Medical Device Excellence Awards

Retrieved on: 
Monday, April 11, 2022

San Antonio, TX, April 11, 2022 (GLOBE NEWSWIRE) -- The 2022 Medical Device Excellence Awards program has selected Seno Medicals Imagio Breast Imaging System as a GOLD award winner in the Radiological, Imaging, and Electromechanical Devices category.

Key Points: 
  • San Antonio, TX, April 11, 2022 (GLOBE NEWSWIRE) -- The 2022 Medical Device Excellence Awards program has selected Seno Medicals Imagio Breast Imaging System as a GOLD award winner in the Radiological, Imaging, and Electromechanical Devices category.
  • The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Seno Medical’s Imagio® Breast Imaging System Named Finalist for Medical Device Excellence Awards

Retrieved on: 
Tuesday, March 29, 2022

San Antonio, Texas, March 29, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.

Key Points: 
  • San Antonio, Texas, March 29, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.
  • The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Seno Medical’s Imagio® Breast Imaging System Named Finalist for Medical Device Excellence Awards

Retrieved on: 
Tuesday, March 29, 2022

San Antonio, Texas, March 29, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.

Key Points: 
  • San Antonio, Texas, March 29, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.
  • The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Seno Medical’s Imagio® Breast Imaging System Named Science and Medical Category Finalist in 2022 Edison Awards Program

Retrieved on: 
Tuesday, February 8, 2022

San Antonio, Texas, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.

Key Points: 
  • San Antonio, Texas, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.
  • The Edison Awards program is an annual competition honoring excellence in new product and service development, marketing, human-centered design, and innovation.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Poster Presentation at RSNA Compares Seno Medical’s OA/US Breast Imaging with AI Decision Support to Ultrasound Alone; Finds Significantly Better Specificity to Support Clinical Decision Making Confidence.

Retrieved on: 
Wednesday, December 1, 2021

The study intended to evaluate the gain in specificity using opto-acoustic ultrasound images and an AI-based decision support tool verses ultrasound alone.

Key Points: 
  • The study intended to evaluate the gain in specificity using opto-acoustic ultrasound images and an AI-based decision support tool verses ultrasound alone.
  • The study found that OA/US, when used with a decision support tool, has statistically significant better specificity compared to conventional ultrasound alone.
  • Fifteen readers with a wide range of experience in breast imaging from both private practice (8) and academic (7) were involved with the reader study.
  • Opto-acoustic ultrasound achieved the primary endpoint in this reader study with specificity significantly higher for OA/US (47.2%) compared to ultrasound alone (38.2%), a difference of 9 percent.

Seno Medical Launches CONFIDENCE Registry Study for Imagio® Breast Imaging System

Retrieved on: 
Thursday, October 21, 2021

San Antonio, TX, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio Breast Imaging System.

Key Points: 
  • San Antonio, TX, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio Breast Imaging System.
  • The companys OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.